Monte Rosa Therapeutics Presents Plans for Four Phase 2 Trial Starts in 2026

Bitget2026/11/05 12:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa Therapeutics expects cash runway into 2029, covering multiple anticipated Phase 2 studies across its three clinical programs.
Potential collaboration payments exceed $350 million over the next 24 months, following more than $400 million received over the past three years.
Novartis is conducting Phase 2a/b trials of MRT-6160 in Sjögren's disease and psoriatic arthritis; additional Phase 2 studies are expected.
MRT-8102 Phase 2 trials are planned for gout in Q4 2026, with coronary artery disease and hidradenitis suppurativa studies in H1 2027.
MRT-2359's Phase 2 trial in AR-mutant metastatic castration-resistant prostate cancer is ongoing, with an update expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26